Published in Pharma Investments, Ventures and Law Weekly, December 26th, 2004
On an operating basis, the company's loss narrowed year-over-year to $1.7 million from $2.1 million as a result of improved product and service revenue.
Net loss for the 2004 third quarter was $1.7 million compared with a net loss of $2.0 million in the comparable 2003 period. Net loss per fully diluted share for the third quarter 2004 was $.19 compared with a net loss of $.22 per fully diluted share for the third quarter of 2003.
The gross margin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.